Moncef Slaoui, the former head of the Trump administration's Operation Warp Speed, says he's "cautiously optimistic" about how well existing vaccines will hold up against omicron, the latest ...

Thea van de Mortel teaches into the Griffith University Master of Infection Prevention and Control program. You’ve tested negative for COVID using a rapid antigen test (RAT), but are a close contact ...

With our free press under threat and federal funding for public media gone, your support matters more than ever. Help keep the LAist newsroom strong, become a monthly member or increase your support ...

The latest variant, or sublineage, of SARS-CoV-2 to emerge on the scene, BA.2.86, has public health experts on alert as COVID-19 hospitalizations begin to rise and the new variant makes its way across ...

You may have heard that there’s a new Omicron spinoff that’s quickly gaining ground in the United States. Maybe you wanted to ask your doctor about it or search for more information online – but what ...

How do scientists detect new variants of the virus that causes COVID-19? The answer is a process called DNA sequencing. The new rules allow state attorneys general in Connecticut and 24 other states ...

New research used engineered mice to compare SARS-COV-2 omicron subvariants and found one of them – BA.5 – was more virulent likely due to its ability to rapidly replicate early during infection. The ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. The COVID-19 vaccines are on track for a big ...

The race is on for new treatments that stand up to omicron's explosive spread. With omicron's explosive spread threatening to outpace current COVID-19 treatments, the race is on to find new options ...

Neil Mabbott does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

Nirmatrelvir-ritonavir use was associated with substantially lower rates of COVID-19-related hospitalization among high-risk outpatients.